Oliver Standring
Overview
Explore the profile of Oliver Standring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koti S, Standring O, Vithlani N, Amini N, Deperalta D, Deutsch G, et al.
J Surg Oncol
. 2024 Nov;
PMID: 39543457
Background: Neoadjuvant chemotherapy (NC) for early pancreatic ductal adenocarcinoma (PDAC) remains controversial. We investigate the adoption of NC and its impact on survival in clinical T1 (cT1) PDAC. Methods: National...
2.
Khalid A, Pasha S, Demyan L, Standring O, King D, Newman E, et al.
J Surg Oncol
. 2024 Nov;
PMID: 39523512
Introduction: Pancreatic adenocarcinoma (PDAC) is a challenging disease, with outcomes influenced by several factors including socioeconomic status. The area deprivation index (ADI) has been used to understand how neighborhood disadvantages...
3.
Khalid A, Pasha S, Demyan L, Standring O, Newman E, King D, et al.
Langenbecks Arch Surg
. 2024 Sep;
409(1):286.
PMID: 39305322
Background: Pancreatic Ductal Adenocarcinoma (PDAC) primarily affects older individuals with diminished physiological reserves. The Modified 5-Item Frailty Index (mFI-5) is a novel risk stratification tool proposed to predict postoperative morbidity...
4.
Fallon J, Standring O, Vithlani N, Demyan L, Shah M, Gazzara E, et al.
Ann Surg Oncol
. 2024 Jun;
31(8):4998-4999.
PMID: 38847982
No abstract available.
5.
Fallon J, Standring O, Vithlani N, Demyan L, Shah M, Gazzara E, et al.
Ann Surg Oncol
. 2024 May;
31(8):4986-4996.
PMID: 38789617
Introduction: Our analysis was designed to characterize the demographics and disparities between the diagnosis of pancreas cancer during emergency presentation (EP) and the outpatient setting (OP) and to see the...
6.
Amini N, Demyan L, Shah M, Standring O, Gazzara E, Lad N, et al.
Am J Surg
. 2023 Oct;
227:77-84.
PMID: 37798150
Background: Since 2013, North American Neuroendocrine Tumor Society (NANETS) consensus-guidelines have endorsed consideration of surgical intervention for pancreatic- neuroendocrine tumors (PNET) with liver metastases. Methods: Patients with non-functional PNET with...
7.
Standring O, Gholami S
Ann Surg Oncol
. 2023 Sep;
30(13):7918-7920.
PMID: 37775685
No abstract available.
8.
Standring O, Gholami S
Surgery
. 2023 Jun;
174(3):747-749.
PMID: 37321884
First introduced in the late 1980s in the setting of unresectable liver metastasis, the use of the hepatic artery infusion pump was expanded to deliver chemotherapy in the adjuvant setting...
9.
Standring O, Sanchez S, Pasha S, Demyan L, Lad N, Ruff S, et al.
Ann Surg Oncol
. 2023 May;
30(8):5105-5112.
PMID: 37233954
Background: Solid pseudopapillary neoplasms (SPN) are rare tumors of the pancreas, typically affecting young women. Resection is the mainstay of treatment but is associated with significant morbidity and potential mortality....
10.
Ruff S, Standring O, Wu G, Levy A, Anantha S, Newman E, et al.
Ann Surg Oncol
. 2021 Jul;
28(13):8318-8328.
PMID: 34312800
Background: Ampullary neuroendocrine tumors (NETs) make up < 1% of all gastroenteropancreatic NETs, and information is limited to case series. This study compares patients with ampullary, duodenal, and pancreatic head...